Plant species first recognised as naturalised for New South Wales in 2002 and 2003, with additional comments on species recognised as naturalised in 2000–2001

Information is provided on the taxonomy and distribution of 71 taxa of naturalised or naturalising plants newly recorded for the state of New South Wales during the period 1 January 2002 to 31 December 2003. Of these taxa, 32 are new records for Australia (prefaced with a †). These species are: Abutilon pictum, Acanthus mollis, †Aesculus indica (naturalising), Agapanthus praecox subsp. orientalis, Ajuga reptans, †Anigozanthos flavidus, Aquilegia vulgaris, Arbutus unedo, †Athertonia diversifolia (naturalising), †Bergenia x schmidtii (naturalising), Bromus catharticus subsp. stamineus, Bryophyllum daigremontianum, Bryophyllum fedtschenkoi, Calyptocarpus vialis, †Ceiba speciosa (naturalising), Cereus uruguayanus, †Cestrum x cultum, †Chamaecyparis lawsoniana, Cistus salviifolius, †Clematis montana, †Coprosma x cunninghamii, Coprosma robusta, Cornus capitata, Cotoneaster simonsii, Cotoneaster x watereri group, Crinum moorei, Cupressus lusitanica, †Cylindropuntia fulgida var. mamillata forma monstrosa, †Cylindropuntia prolifera, Cylindropuntia tunicata, Desmanthus virgatus, Drosanthemum candens, †Elaeagnus umbellata (naturalising), †Eragrostis trichophora, †Eupatorium lindleyanum, †Gibasis pellucida, Glechoma hederacea, †Hesperis matronalis, Hieracium aurantiacum subsp. carpathicola, †Inga edulis (naturalising), †Juniperus conferta (naturalising), †Justicia caudata, Lamium galeobdolon, Lathyrus tingitanus, †Lysimachia fortunei, †Maackia amurensis, †Monstera deliciosa, †Murdannia keisak, Odontonema tubaeforme, Oxalis vallicola, Phoenix canariensis, †Physostegia virginiana, Pinus patula, Pittosporum eugenioides, †Pittosporum ralphii, Pittosporum tenuifolium, Plectranthus ecklonii, †Potentilla vesca, †Prunus campanulata, †Rhododendron ponticum, Rosa luciae, Rubus rugosus, Ruellia squarrosa, †Senna multijuga, Stapelia gigantea, Stephanophysum longifolium, Strobilanthes anisophylla, †Tabebuia chrysotricha, †Tabebuia impetiginosa, †Tradescantia pallida and Ulmus x hollandica. Additional notes and name changes are recorded for plants first recognised as naturalised for New South Wales over the period 2000–2001. The identification of several naturalised taxa occurring in New South Wales has been corrected. Plants formerly identified as Pinus nigra var. corsicana are now considered to be Pinus halepensis; Cylindropuntia arbuscula is Cylindropuntia kleiniae, Cylindropuntia tunicata is Cylindropuntia rosea, Abrus precatorius subp. precatorius is now Abrus precatorius subsp. africanus and Cotoneaster ?horizontalis is Cotoneaster microphyllus. Further field studies have revealed that Cylindropuntia leptocaulis, Cylindropuntia spinosior, Hypericum kouytchense and Chamaesyce ophthalmica are more widespread than previously thought

Status of names of Mitrasacme species occurring outside Australia

Species of Mitrasacme occurring in Australia were revised for the Flora of Australia project in 1996, but the genus has never been revised as a whole. A checklist of the names of Mitrasacme species that occur outside Australia is presented here, together with their taxonomic status, known distribution and notes on their morphological affinities

Plant species first recognised as naturalised or naturalising for New South Wales in 2004 and 2005

Information is provided on the taxonomy and distribution of 62 taxa of naturalised or naturalising plantsm newly recorded for the state of New South Wales during the period 1 January 2004 and 31 December 2005 and 1 species treated in the 2002 revised Flora of New South Wales Volume 2 but overlooked in an earlier paper of this series. Of these taxa, 17 are new records for Australia (prefaced with a †). The 62 taxa are: Acer palmatum, †Acer saccharinum, Achillea filipendulina, Acokanthera oblongifolia, †Anemone hupehensis var. japonica, Berberis aquifolium, †Bidens aurea, †Brugmansia suaveolens, Brugmansia x candida, Buddleja dysophylla, †Convolvulus farinosus, Cordyline australis, Coriandrum sativum, Corymbia citriodora (Australian species naturalised outside its native range), Crassula ericoides subsp. ericoides, Crotalaria retusa (Australian species naturalised outside its native range), Cyperus prolifer, Echinochloa polystachya, Ficus carica, †Gladiolus dalenii, †Gladiolus cultivar, Hakea laurina (Western Australian species), Hemerocallis fulva var. fulva, Hieracium pilosella, Hydrangea macrophylla, Hydrocleys nymphoides, Hymenachne amplexicaulis, Hypericum calycinum, Impatiens balfouri, Indigofera spicata, Iris laevigata, †Juglans ailantifolia, Lilium lancifolium, Lygodium japonicum, Malephora crocea, Mauranthemum paludosum, Melastoma malabathricum, †Nassella tenuissima, Pelargonium quercifolium, †Phoenix reclinata, Phormium tenax, Pinus contorta, Podranea ricasoliana, †Polygonatum x hybridum, Polypremum procumbens, †Primula malacoides, Rhaphiolepis umbellata, Romneya coulteri, Romneya trichocalyx, Setaria incrassata, †Sideritis lanata, †Sorbus aucuparia, Spartium junceum, Stylosanthes guianensis, Stylosanthes humilis, †Symphoricarpos albus var. laevigatus, Syzygium paniculatum (Australian species naturalising outside its native range), Tibouchina urvilleana, †Tradescantia cerinthoides, †Utricularia sandersonii, Washingtonia filifera and Zephyranthes carinata. The overlooked species is Eugenia uniflora

Molecular phylogenetics reveals a new species of Prostanthera from tropical Queensland with links to more southerly taxa

Prostanthera eungella B.J.Conn & K.M.Proft (Lamiaceae) is described as a new species from the South Kennedy botanical region of northern Queensland. Concatenated nuclear (ETS) and chloroplast (trnH–psbA) sequence data for 38 species of Prostanthera were analysed using maximum-likelihood and Bayesian-inference methods. These combined data recovered P. eungella as part of a polytomy that included P. galbraithiae, P. howelliae¸ and a P. tallowa + P. lasianthos clade. A detailed description, photograph of holotype specimen, and distribution map of P. eungella are provided

Mapping the internal recognition surface of an octanuclear coordination cage using guest libraries

Size and shape criteria for guest binding inside the cavity of an octanuclear cubic coordination cage in water have been established using a new fluorescence displacement assay to quantify guest binding. For aliphatic cyclic ketones of increasing size (from C5 to C11), there is a linear relationship between ΔG for guest binding and the guest’s surface area: the change in ΔG for binding is 0.3 kJ mol–1 Å–2, corresponding to 5 kJ mol–1 for each additional CH2 group in the guest, in good agreement with expectations based on hydrophobic desolvation. The highest association constant is K = 1.2 × 106 M–1 for cycloundecanone, whose volume is approximately 50% of the cavity volume; for larger C12 and C13 cyclic ketones, the association constant progressively decreases as the guests become too large. For a series of C10 aliphatic ketones differing in shape but not size, ΔG for guest binding showed no correlation with surface area. These guests are close to the volume limit of the cavity (cf. Rebek’s 55% rule), so the association constant is sensitive to shape complementarity, with small changes in guest structure resulting in large changes in binding affinity. The most flexible members of this series (linear aliphatic ketones) did not bind, whereas the more preorganized cyclic ketones all have association constants of 104–105 M–1. A crystal structure of the cage·cycloundecanone complex shows that the guest carbonyl oxygen is directed into a binding pocket defined by a convergent set of CH groups, which act as weak hydrogen-bond donors, and also shows close contacts between the exterior surface of the disc-shaped guest and the interior surface of the pseudospherical cage cavity despite the slight mismatch in shape

Multidimensional individualised Physical ACTivity (Mi-PACT) - a technology-enabled intervention to promote physical activity in primary care: Study protocol for a randomised controlled trial

© 2015 Peacock et al. Background: Low physical activity is a major public health problem. New cost-effective approaches that stimulate meaningful long-term changes in physical activity are required, especially within primary care settings. It is becoming clear that there are various dimensions to physical activity with independent health benefits. Advances in technology mean that it is now possible to generate multidimensional physical activity 'profiles' that provide a more complete representation of physical activity and offer a variety of options that can be tailored to the individual. Mi-PACT is a randomised controlled trial designed to examine whether personalised multidimensional physical activity feedback and self-monitoring alongside trainer-supportive sessions increases physical activity and improves health outcomes in at-risk men and women. Methods/Design: We aim to recruit 216 patients from within primary care aged 40 to 70years and at medium or high risk of cardiovascular disease and/or type II diabetes mellitus. Adopting an unequal allocation ratio (intervention: control) of 2:1, participants will be randomised to one of two groups, usual care or the intervention. The control group will receive usual care from their general practitioner (GP) and standardised messages about physical activity for health. The intervention group will receive physical activity monitors and access to a web-based platform for a 3-month period to enable self-monitoring and the provision of personalised feedback regarding the multidimensional nature of physical activity. In addition, this technology-enabled feedback will be discussed with participants on 5 occasions during supportive one-to-one coaching sessions across the 3-month intervention. The primary outcome measure is physical activity, which will be directly assessed using activity monitors for a 7-day period at baseline, post intervention and at 12months. Secondary measures (at these time-points) include weight loss, fat mass, and markers of metabolic control, motivation and well-being. Discussion: Results from this study will provide insight into the effects of integrated physical activity profiling and self-monitoring combined with in-person support on physical activity and health outcomes in patients at risk of future chronic disease. Trial registration:ISRCTN18008011Trial registration date: 31 July 201

The global naturalized Alien Flora (GloNAF) database

This dataset provides the Global Naturalized Alien Flora (GloNAF) database, ver-sion 1.2. Glo NAF represents a data compendium on th e occurrence and identit y of naturalizedalien vascular plant taxa across geographic regions (e.g. countries, states, provinces, districts,islands) around the globe. The dataset includes 13,939 taxa and covers 1,029 regions (including381 islands). The dataset is based on 210 data sources. For each ta x on-b y-region combination, wepr ovide information on whether the tax on is consider ed to be naturalized in the specific region(i.e. has established self-sustaining popula tions in the wild). Non-native taxa are marked as“alien”, when it is not clear whether they are naturalized. To facilitate alignment with other plantdatabases, we pro v ide f or each taxon the name as given in the original data source and the stan-dardized taxon and family names used by The Plant List Version 1.1 (http://www.theplantlist.org/). We pro vide an ESRI shapefile including polygons f or each region and informa tion on whetherit is an island or a mainland region, the country and the Taxonomic Databases Working Group(TDWG) regions it is part of (TDWG levels 1–4). We also provide several variables that can beused to filter the data according to quality and completeness of alien taxon lists, which varyamong the combinations of regions and da ta sources. A pre vious version of the GloNAF dataset(version 1.1) has already been used in several studies on, for example, historical spatial flows oftaxa between continents and geographical patterns and determinants of naturalization across dif-ferent taxonomic groups. We intend the updated and expanded GloNAF version presented hereto be a global resource useful for studying plant inv asions and changes in biodiversity from regio-nal to global scales. We release these data into the public domain under a Crea ti ve CommonsZer o license waiver (https://creati v ecommons.org/share-y our -work/public-domain/cc0/). Wheny ou use the da ta in your publication, we request that y ou cite this da ta paper. If GloN AF is amajor part of the data analyzed in your study, you should consider inviting the GloNAF coreteam (see Metadata S1: Originators in the Overall project description) as collaborators. If youplan to use the GloNAF dataset, we encourage y ou to contact the GloNAF core team to checkwhether there have been recent updates of the dataset, and whether similar analyses are already ongoing

Outcomes of obstructed abdominal wall hernia: results from the UK national small bowel obstruction audit

Background: Abdominal wall hernia is a common surgical condition. Patients may present in an emergency with bowel obstruction, incarceration or strangulation. Small bowel obstruction (SBO) is a serious surgical condition associated with significant morbidity. The aim of this study was to describe current management and outcomes of patients with obstructed hernia in the UK as identified in the National Audit of Small Bowel Obstruction (NASBO). Methods: NASBO collated data on adults treated for SBO at 131 UK hospitals between January and March 2017. Those with obstruction due to abdominal wall hernia were included in this study. Demographics, co-morbidity, imaging, operative treatment, and in-hospital outcomes were recorded. Modelling for factors associated with mortality and complications was undertaken using Cox proportional hazards and multivariable regression modelling. Results: NASBO included 2341 patients, of whom 415 (17·7 per cent) had SBO due to hernia. Surgery was performed in 312 (75·2 per cent) of the 415 patients; small bowel resection was required in 198 (63·5 per cent) of these operations. Non-operative management was reported in 35 (54 per cent) of 65 patients with a parastomal hernia and in 34 (32·1 per cent) of 106 patients with an incisional hernia. The in-hospital mortality rate was 9·4 per cent (39 of 415), and was highest in patients with a groin hernia (11·1 per cent, 17 of 153). Complications were common, including lower respiratory tract infection in 16·3 per cent of patients with a groin hernia. Increased age was associated with an increased risk of death (hazard ratio 1·05, 95 per cent c.i. 1·01 to 1·10; P = 0·009) and complications (odds ratio 1·05, 95 per cent c.i. 1·02 to 1·09; P = 0·001). Conclusion: NASBO has highlighted poor outcomes for patients with SBO due to hernia, highlighting the need for quality improvement initiatives in this group

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)